Regentis Biomaterials (NYSEAMERICAN:RGNT) Shares Down 35.1% – What’s Next?

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT)’s stock price dropped 35.1% on Tuesday . The company traded as low as $6.10 and last traded at $6.10. 8,239,709 shares changed hands during trading, a decline of 47% from the average daily volume of 15,669,613 shares. The stock had previously closed at $9.40.

Analyst Ratings Changes

Separately, ThinkEquity upgraded Regentis Biomaterials to a “strong-buy” rating in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Regentis Biomaterials Stock Performance

The stock has a 50 day moving average price of $2.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials as of its most recent filing with the SEC.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.